Compare Ascendis Pharma A/S (ASND) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Ultra Short Bond ETF — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | VUSB | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $50.03 |
52-Week Low | $189.74 | $49.60 |
Enterprise Value | $17.04B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
